Form 4: MPM BioVentures Sells Werewolf Therapeutics Shares

MPM BioVentures entities, a 10% owner and director of Werewolf Therapeutics, reported the sale of 242,890 common shares over three days in early November 2025, pursuant to a Rule 10b5-1 plan.

Summary

• MPM BioVentures 2014, L.P. and related entities, identified as a 10% owner and director of Werewolf Therapeutics, Inc. (HOWL), reported multiple sales of common stock.
• Transactions occurred on November 4, 5, and 6, 2025, totaling 242,890 shares.
• All sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On November 4, 2025, 140,488 shares were sold at a weighted average price of $1.22 per share, with prices ranging from $1.17 to $1.30.
• On November 5, 2025, 47,950 shares were sold at a weighted average price of $1.22 per share, with prices ranging from $1.19 to $1.25.
• On November 6, 2025, 54,452 shares were sold at a weighted average price of $1.21 per share, with prices ranging from $1.185 to $1.27.
• Following these transactions, the reporting persons indirectly beneficially own 5,904,720 shares of Werewolf Therapeutics common stock.
• The shares are held across various MPM entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.
• Ansbert Gadicke, a managing director and managing partner across several MPM entities, is linked to these transactions.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling by a major shareholder and director group. While the sales were pre-planned under a 10b5-1 plan, the sheer volume and the fact that a major insider is reducing their stake can still be perceived as a negative signal by the market, even if it's for diversification or liquidity purposes. The relatively low sale prices also contribute to a less positive outlook.

Negatives

• Significant insider selling by a 10% owner and director group, totaling 242,890 shares, could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic reduction in exposure.
• The sales occurred at relatively low prices, ranging from $1.17 to $1.30, which might suggest the reporting persons are taking profits or reducing risk at current valuation levels.

Related Party Transactions

• The transactions involve the sale of common stock by MPM BioVentures entities, which are identified as a 10% owner and director of Werewolf Therapeutics, Inc. Ansbert Gadicke, a managing director across several MPM entities, is also linked to these transactions.

Stakeholder Impact

• Shareholders: Existing shareholders might view the significant insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Company: The reduction in ownership by a major institutional investor and director group could impact investor confidence and future capital-raising efforts, though the impact is mitigated by the 10b5-1 plan.

Key Dates

Recommendation

While the insider selling by MPM BioVentures entities is substantial, it was executed under a pre-arranged Rule 10b5-1 plan, which mitigates the immediate negative signal typically associated with insider sales. This suggests the sales are for portfolio management or liquidity rather than a sudden loss of confidence. However, the sheer volume of shares sold by a 10% owner and director group, even if planned, warrants caution. Investors should 'hold' to observe future developments and company performance rather than reacting solely to these planned sales, which do not necessarily reflect a change in the company's fundamental outlook.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, Insider Selling, MPM BioVentures, 10b5-1 Plan, Stock Sale, Biotechnology, Oncology, Ansbert Gadicke